The US Food and Drug Administration confirmed that Optimer Pharmaceuticals' new antibiotic drug, fidaxomicin, is effective in combating a bacterial infection that is the direct cause of diarrhea.
While the FDA will conduct a more thorough evaluation of the data available during its advisory panel meeting on Tuesday, the health regulator released documents in which it said that fidaxomicin was able to treat the infection, known as Clostridium difficile.
AdvertisementShare prices of Optimer saw an 11 percent rise to $13.20 before ending the session at $13.13.
Should the drug be given approval by the FDA, then this will be the first from Optimer to reach the US market and analysts predict that the drug would fetch over $200 million in annual sales.
P Penetration of Toxins into Our Cells may be Mediated by Mucus Restaurants Must Display Calorie Counts on Menus M
You May Also Like